The fact that muscle signaling to aPKC and Akt improve after use of liver-specific aPKC inhibitors also suggests that muscle defects follow hepatic defects in both obesity models. This evidence concerns the gene AKT1 and obesity due to melanocortin 4 receptor deficiency.